The goal of the Developmental Research Program in the Mayo Clinic SPORE in Ovarian Cancer is to support innovative, scientifically sound research projects from which findings can be translated into clinically relevant intervenfions that will reduce the burden of ovarian cancer. The Developmental Research Program will 1) foster innovafive laboratory, populafion, and clinical study proposals that have strong translafional potenfial;2) encourage and support interdisciplinary collaboration in translational research in ovarian cancer; and 3) generate new hypotheses that can be tested in larger scale research projects or clinical trials in ovarian cancer. The Developmental Research Program will provide $200,000 annually ($100,000 from the SPORE and a matching $100,000 from Mayo) to support four meritorious projects each year. Depending on the progress on a given project, there will be the possibility of a second year of support. The Developmental Research Program will ufilize a defined process to call for applicafions on an annual basis and to review submissions, ufilizing the expertise of the Internal Scientific Advisory Committee and other experienced investigators as needed. Criteria for selection will include: the likelihood that the work will impact major challenges in ovarian cancer, scientific merit, originality, translafional potential, quallficafions of the key personnel, and interactivity. It is anticipated that support of pilot projects through this program will generate new hypotheses that can be addressed in exisfing SPORE-sponsored projects or through peer-reviewed external grant support. Brief descriptions of several potenfial developmental research projects are included to demonstrate the depth and breadth of ongoing research in ovarian cancer at Mayo Clinic

Public Health Relevance

The Developmental Research Program will support studies with high potenfial to impact ovarian cancer treatment and outcome. Four projects that encourage collaborations and generate new ideas to be tested will be supported each year.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Lengyel, Ernst; Litchfield, Lacey M; Mitra, Anirban K et al. (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol 212:479.e1-479.e10
Earp, Madalene A; Kelemen, Linda E; Magliocco, Anthony M et al. (2014) Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet 133:481-97
Liu, Yu-Ping; Wang, Jiahu; Avanzato, Victoria A et al. (2014) Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol 132:722-9
Fridley, Brooke L; Armasu, Sebastian M; Cicek, Mine S et al. (2014) Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome. BMC Med Genomics 7:21
Trabert, Britton; Ness, Roberta B; Lo-Ciganic, Wei-Hsuan et al. (2014) Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst 106:djt431
Parker, Peter J; Justilien, Verline; Riou, Philippe et al. (2014) Atypical protein kinase Cýý as a human oncogene and therapeutic target. Biochem Pharmacol 88:1-11
Scott, Clare L; Mackay, Helen J; Haluska Jr, Paul (2014) Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book :e258-66
Charbonneau, Bridget; Moysich, Kirsten B; Kalli, Kimberly R et al. (2014) Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res 2:332-40
Brewer, LaPrincess C; Hayes, Sharonne N; Parker, Monica W et al. (2014) African American women's perceptions and attitudes regarding participation in medical research: the Mayo Clinic/The Links, Incorporated partnership. J Womens Health (Larchmt) 23:681-7
King, Helen; Aleksic, Tamara; Haluska, Paul et al. (2014) Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev 40:1096-105

Showing the most recent 10 out of 86 publications